RFA-CE-24-012: Rigorous Evaluation of Policy-Level Interventions to Prevent Overdose (R01)
Closed
This grant is closed. A newer notice from the same program is open now: NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) (PA-27-100). Status: Due dates in the notice, expires April 5, 2027. It is in our archive of Centers for Disease Control and Prevention - ERA notices from 2023.
Centers for Disease Control and Prevention - ERA offered grants of up to $350,000 to any type of organization. It expected to make about 2 awards worth $2.1 million in total. Applications closed on December 1, 2023.
From the official notice on Grants.gov, last changed September 29, 2023. Checked November 7, 2026.
- Award ceiling$350,000
- Total funding$2.1 million
- Expected awards2
- Cost sharingNot required
- Funding typeGrant
Key dates
| Posted | August 30, 2023 |
|---|---|
| Deadline | December 1, 2023 |
| Archived by Grants.gov | December 31, 2023 |
Who can apply
This opportunity was open to any type of organization.
All 16 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
See Section III. Eligibility Information
Is this a realistic fit?
- Past Injury Prevention and Control Research and State and Community Based Programs awards averaged $2.2 million; this notice allows up to $350,000 per award.
- Most of the program's money (76% over five years) went to state and local governments.
- No cost sharing or match is required.
What the grant funds
The Centers for Disease Control and Prevention’s (CDC) National Center for Injury Prevention and Control (NCIPC, Injury Center) is soliciting investigator-initiated research to rigorously evaluate effectiveness of policies for reducing drug use and overdose as well as the effect of these strategies on reducing or worsening existing disparities in medical care and health outcomes. Equally important to quantifying the impacts of these policies on health outcomes is understanding their implementation and how implementation affects achieving the intended outcomes of the policy among groups experiencing disproportionate burden of overdose and/or groups that are at greater risk of experiencing adverse outcomes related to substance use due to social determinants of health. The proposed research should evaluate the impact of a selected local, state, tribal, federal, or organizational policy (e.g., school or health systems) aimed at reducing or regulating substance use or reducing drug overdose, on rates of at least two overdose outcomes (i.e., nonfatal overdose, fatal overdose, substance use disorders, substance use, initiation of substance use among youth).
Who has won Injury Prevention and Control Research and State and Community Based Programs grants before
From fiscal 2021 to 2025, Injury Prevention and Control Research and State and Community Based Programs (93.136) awarded $2.2 billion across 986 grant awards, an average of $2.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Florida Department of Health | Florida | 12 | $81.1 million |
| California Department of Public Health | California | 11 | $55.4 million |
| Ohio Department of Health | Ohio | 9 | $42.0 million |
| North Carolina Department of Health & Human Services | North Carolina | 12 | $42.0 million |
| Michigan Department of Health and Human Services | Michigan | 10 | $37.9 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, PA-27-100, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-CE-24-012 still open?
No. It closed on December 1, 2023. A newer notice is open: PA-27-100, due dates in the notice, expires April 5, 2027.
Who can apply for Rigorous Evaluation of Policy-Level Interventions to Prevent Overdose (R01)?
Centers for Disease Control and Prevention - ERA accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Rigorous Evaluation of Policy-Level Interventions to Prevent Overdose (R01)?
Closed December 1, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $350,000 each. About $2.1 million in total across about 2 awards.
Who has won Injury Prevention and Control Research and State and Community Based Programs grants before?
The largest recipients over five fiscal years were Florida Department of Health, California Department of Public Health, Ohio Department of Health. The program made 986 awards worth $2.2 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)